The results showed that MMP-3 levels in RA patients, including ACPA+ and ACPA- patients, were significantly higher than in HCs (p < 0.001), but there was no significant difference between the two RA groups (p = 0.697). This evidence concerns the gene PRTN3 and rheumatoid arthritis.